Novo reports early bone-protection signals from amylin and calcitonin receptor agonists
- After eight weeks in ovariectomized rats, femoral trabecular bone volume was 43% higher with cagrilintide and 40% higher with CagriSema than in weight-matched controls; both differences were significant.
- Small studies in healthy volunteers linked cagrilintide and zenagamtide, but not selective amylin receptor agonist NN1213, to lower levels of the bone-resorption marker CTX-I.
- In a 252-participant REDEFINE 1 DXA substudy, bone mineral density declined with CagriSema but remained within the normal range for age and sex at week 68.
- REDEFINE 1 was not designed to assess fracture risk, and the exploratory findings require further study.
Preclinical findings
In an eight-week model of postmenopausal bone loss, cagrilintide and CagriSema attenuated trabecular bone loss and deterioration of bone microarchitecture. Femoral trabecular bone volume was 43% higher with cagrilintide and 40% higher with CagriSema than in weight-matched controls, with both differences statistically significant. Increases with zenagamtide and semaglutide were not significant.
Human biomarker and trial analyses
Small studies in healthy volunteers found that cagrilintide and zenagamtide suppressed CTX-I, a marker of bone resorption; selective amylin receptor agonist NN1213 did not show the same effect. The comparison suggests calcitonin receptor activation may contribute to the observed effect.
In post hoc analyses of phase 3 REDEFINE 1, bone mineral density decreased among CagriSema-treated participants in a 252-person DXA substudy but remained within the normal range for age and sex at week 68. CTX-I increased similarly to placebo with cagrilintide and modestly more with CagriSema than with semaglutide, despite greater weight loss. The bone-formation marker P1NP rose above baseline by week 68, while proteins associated with bone formation and mineralization increased with cagrilintide and CagriSema.
Limitations
The analyses are exploratory, and REDEFINE 1 was not designed to assess fracture risk. Longer follow-up and further research are needed to establish whether the findings translate into long-term bone health outcomes. The medicines are investigational.
Source: Novo Nordisk